Manders DB, et al. - Experts evaluated expected response rates (RRs) and toxicities with third-line salvage chemotherapy in patients with metastatic and recurrent cervical cancer who progress through 2 salvage regimens. Participants were all patients with cervical cancer who had a minimum of three unique salvage chemotherapy regimens following primary surgery or radiation between January 1, 2000 and June 30, 2013 at a single institution. Minimal benefit at the cost of significant toxicity could be expected in patients eligible to receive third-line chemotherapy for metastatic and recurrent cervical cancer. RR to third-line chemotherapy was 10%, with another 27% achieving stable disease, while 57% experienced grade 3 or 4 toxicity. When counseling about the risks and benefits of further cytotoxic therapy, quality of life needs to be considered.